Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells

DOI PDF 被引用文献7件
  • Silke Appel
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Andreas M. Boehmler
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Frank Grünebach
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Martin R. Müller
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Anette Rupf
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Markus M. Weck
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Ulrike Hartmann
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Volker L. Reichardt
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Lothar Kanz
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Tim H. Brümmendorf
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.
  • Peter Brossart
    From the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany.

抄録

<jats:title>Abstract</jats:title><jats:p>Imatinib mesylate (STI571) is a competitive Bcr-Abl tyrosine kinase inhibitor and has yielded encouraging results in treatment of chronic myelogenous leukemia (CML) and gastrointestinal stroma tumors (GISTs). Apart from inhibition of the Abl protein tyrosine kinases, it also shows activity against platelet-derived growth factor receptor (PDGF-R), c-Kit, Abl-related gene (ARG), and their fusion proteins while sparing other kinases. In vitro studies have revealed that imatinib mesylate can inhibit growth of cell lines and primitive malignant progenitor cells in CML expressing Bcr-Abl. However, little is known about the effects of imatinib mesylate on nonmalignant hematopoietic cells. In the current study we demonstrate that in vitro exposure of mobilized human CD34+ progenitors to therapeutic concentrations of imatinib mesylate (1-5 μM) inhibits their differentiation into dendritic cells (DCs). DCs obtained after 10 to 16 days of culture in the presence of imatinib mesylate showed concentration-dependent reduced expression levels of CD1a and costimulatory molecules such as CD80 and CD40. Furthermore, exposure to imatinib mesylate inhibited the induction of primary cytotoxic T-lymphocyte (CTL) responses. The inhibitory effects of imatinib mesylate were accompanied by down-regulation of nuclear localized RelB protein. Our results demonstrate that imatinib mesylate can act on normal hematopoietic cells and inhibits the differentiation and function of DCs, which is in part mediated via the nuclear factor κB signal transduction pathway.</jats:p>

収録刊行物

  • Blood

    Blood 103 (2), 538-544, 2004-01-15

    American Society of Hematology

被引用文献 (7)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ